Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs)
NEXT-GENERATION IMID MEDICINES
We’re on a mission to improve the lives of patients with IMIDs.
By leveraging proprietary patient data, we identify the right drug target specific to the right patient, discovering and developing medicines that can restore quality of life for millions of patients.
Direct ongoing patient access across eight IMIDs, and comprehensive IMID Biobank
Proprietary, comprehensive clinical, biomolecular data and application of bioinformatics for discovery
Pipeline of innovative targets derived from proprietary IMID patient data with defined selection criteria
IMIDs are a significant detriment to quality of life for millions of patients
In the US affected by IMIDs
Annual US economic burden from IMIDs
Ulcerative Colitis patients fail to achieve remission
Systemic Lupus Erythematosus patients require >1YR for correct diagnosis
Reduced life expectancy for RA patients
WHAT MAKES IMIDOMICS DIFFERENT
Our Clinical Discovery Engine is built on proprietary IMIDomics patient data collected by the IMID Consortium specifically for drug target discovery and patient stratification purposes
The Spanish IMID Investigator Consortium: a living resource for IMIDomics
years of data and sample collection
- Systemic Lupus Erythematosus
- Ulcerative Colitis
- Crohn’s Disease
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Atopic Dermatitis
- Sjögren’s Syndrome
we have the ability to recontact patients
LEVERAGING DRUG DEVELOPMENT EXPERTISE AT EVERY LEVEL
Precision discovery feeds full-scale development of our pipeline
COLLABORATING WITH GLOBAL EXPERTS
Key partners and advisors at every stage
“IMIDomics have assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking and analytics.”
“IMIDomics is uniquely positioned to generate new and important insights that aid in the development of therapeutics to treat IMIDs.”
“Evotec and IMIDomics are perfectly aligned on their goal to leverage data to discover and develop precise-acting, effective medicines of the future.”
“To access similar data and capabilities elsewhere would require multiple collaborations with individual clinics, universities, analysis labs, and expert data analytical groups.”
Dr. Craves is the Executive Chairman and CEO of IMIDomics and has been involved in the company since it was founded. He was formerly the Founder of Bay City Capital life science investment firm.
As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry, including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture-backed biotech company at that time. Today, Dr. Craves brings decades of experience to the leadership of IMIDomics.
Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of IMIDomics, Inc., Madrigal Pharmaceuticals, and Synchronicity Pharma. Previous investments and board participation, in addition to Reliant Pharmaceuticals, include Medarex, Inc., Incyte Biosciences, Dermira Pharmaceuticals, Twist Bioscience and Ion Torrent. He earned a BS in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco.